Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)
NCT ID: NCT04624295
Last Updated: 2025-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
294 participants
INTERVENTIONAL
2021-01-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset
NCT02930837
Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)
NCT06548971
Low-dose Aspirin Therapy in Patients With Ischemic Stroke and Microbleeds
NCT04504864
EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs
NCT05429476
Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset
NCT02854592
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early Antiplatelet Therapy
Early aspirin Therapy
Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
Non-Early Antiplatelet Therapy
Non-Early aspirin Therapy
Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Early aspirin Therapy
Early Antiplatelet Therapy is administered within 24 to 48 hours after stroke onset and the dose is determined by the clinician. Aspirin was chosen for antiplatelet therapy.
Non-Early aspirin Therapy
Antiplatelet therapy will be delayed to beyond 48 hours after stroke onset and may not be initiated until hemorrhagic Infarction has been confirmed absorbed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Be confirmed as Hemorrhagic Infarction at 24 to 36 hours after intravenous thrombolysis by computerized tomography
3. The patient or family member signed an informed consent
Exclusion Criteria
2. Tirofiban was used after receiving endovascular treatment;
3. Intraoperative stent placement after receiving endovascular treatment;
4. Subarachnoid hemorrhage or ventricular hemorrhage;
5. There are contraindications for aspirin use;
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shaoxing People's Hospital
OTHER
Affiliated Hospital of Jiaxing University
OTHER
Huzhou Central Hospital
OTHER
The Second Affiliated Hospital of Jiaxing University
OTHER
Jinhua Central Hospital
OTHER
Taizhou Hospital
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Ningbo No.2 Hospital
OTHER
Lishui Country People's Hospital
OTHER
Wenzhou Central Hospital
OTHER
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
OTHER
Shenzhen Second People's Hospital
OTHER
The Affiliated Hospital of Xuzhou Medical University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Min Lou, PhD
Role: STUDY_DIRECTOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the second affiliated hospital of Zhejiang University
Hangzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Min Lou
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HITs
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.